HomeCompareTHNPY vs MRK

THNPY vs MRK: Dividend Comparison 2026

THNPY yields 2.21% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 THNPY wins by $99.89M in total portfolio value· pulled ahead in Year 2
10 years
THNPY
THNPY
● Live price
2.21%
Share price
$42.33
Annual div
$0.94
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$99.95M
Annual income
$91,964,510.00
Full THNPY calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — THNPY vs MRK

📍 THNPY pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTHNPYMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, THNPY + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
THNPY pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

THNPY
Annual income on $10K today (after 15% tax)
$188.10/yr
After 10yr DRIP, annual income (after tax)
$78,169,833.50/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, THNPY beats the other by $78,161,236.79/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of THNPY + MRK for your $10,000?

THNPY: 50%MRK: 50%
100% MRK50/50100% THNPY
Portfolio after 10yr
$50.00M
Annual income
$45,987,311.89/yr
Blended yield
91.97%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

THNPY
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
1.6
Piotroski
6/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

THNPY buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTHNPYMRK
Forward yield2.21%2.81%
Annual dividend / share$0.94$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$99.95M$57.7K
Annual income after 10y$91,964,510.00$10,113.78
Total dividends collected$99.32M$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: THNPY vs MRK ($10,000, DRIP)

YearTHNPY PortfolioTHNPY Income/yrMRK PortfolioMRK Income/yrGap
1$11,143$442.59$11,213$373.04$70.00MRK
2← crossover$12,844$921.79$12,667$512.06+$177.00THNPY
3$15,730$1,986.11$14,439$708.14+$1.3KTHNPY
4$21,377$4,546.25$16,640$988.16+$4.7KTHNPY
5$34,422$11,548.56$19,432$1,394.07+$15.0KTHNPY
6$71,590$34,758.69$23,057$1,992.90+$48.5KTHNPY
7$211,724$135,122.70$27,889$2,894.79+$183.8KTHNPY
8$973,496$746,950.92$34,518$4,286.29+$939.0KTHNPY
9$7,461,153$6,419,513.13$43,912$6,494.35+$7.42MTHNPY
10$99,947,944$91,964,510.00$57,714$10,113.78+$99.89MTHNPY

THNPY vs MRK: Complete Analysis 2026

THNPYStock

Technip Energies N.V., together with its subsidiaries, operates as an engineering and technology company for the energy transition in Europe, Russia, the Asia Pacific, Africa, the Middle East, and the Americas. The company operates through two segments, Projects Delivery, and Technology, Products and Services. It is involved in the engineering, procurement, construction management, commissioning, and transport and installation of various energy projects. The company also engages in designing, engineering, procurement, construction, and project management of various onshore and offshore facilities related to gas monetization, ethylene, hydrogen, refining, and chemical processing from biofuels and hydrocarbons. In addition, it develops, designs, commercializes, and integrates a range of technologies in gas monetization, refining, petrochemicals, and fertilizers, hydrogen, and sustainable chemistry; provides land and marine-based loading and transfer systems services to the oil and gas, petrochemical, chemical, and decarbonization industries; and offers a range of project management consulting services to the energy industry. Further, it offers robotics, asset monitoring, and surveillance solutions, as well as nondestructive testing and material testing solutions for harsh environments of a range of industries, such as nuclear, oil and gas, offshore wind, or aerospace; commercializes a complete solution for inspection, and maintenance and repair for its proprietary software supervision Cyxense Commander, which is used to remotely control an heterogeneous fleet of robots; develops a range of proprietary third party robots; and provides digital services. Technip Energies N.V. was incorporated in 2019 and is headquartered in Nanterre, France.

Full THNPY Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this THNPY vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

THNPY vs SCHDTHNPY vs JEPITHNPY vs OTHNPY vs KOTHNPY vs MAINTHNPY vs JNJTHNPY vs ABBVTHNPY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.